United States· US:69945-096_47bb627f-3944-5901-e063-6294a90a38cb
Technescan MAG3
A betiatide product containing betiatide, registered in United States by Curium US LLC. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Betiatide is registered in 3 of 19 countries.
Countries holding a registration under ATC Betiatide (betiatide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 1 of them publish a price we can compare per daily dose
Betiatide · ATC Betiatide
3 / 19 countries
- Germany
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- BETIATIDE
- Manufacturer
- Curium US LLC
- Country
- United States (US)
- ATC code
- Betiatide
- ATC class
- Betiatide
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1169945096205 VIAL in 1 CELLO PACK (69945-096-20) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL
- ndc1169945-096-20
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Betiatide in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRENOSCINT MAG3Medi-Radiopharma Kft., Érd
- SpainMAG3 RADIOPHARMACY 1 MG EQUIPO DE REACTIVOS PARA PREPARACION RADIOFARMACEUTICA EFGMedi-Radiopharma Kft.
- GermanyRenoscint Mag3Medi-Radiopharma Kft.
- United KingdomRenoscan MAG3 1mg kit for radiopharmaceutical preparationGE Healthcare Ltd
- IrelandTechneScan MAG3, powder for solution for injectionCurium Netherlands B.V.
- NetherlandsTechnescan MAG3 1 mg kit voor radiofarmaceutisch preparaatCurium Netherlands B.V.
- PolandRenoscint MAG3Medi-Radiopharma Kft.
- SwedenTechneScan MAG3 1 mg Beredningssats för radioaktivt läkemedelCurium Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Renoscint Mag3, Technescan Mag3
- Belgium · Technescan Mag3
- Czechia · Renoscint Mag3, Technescan Mag3
- Germany · Renoscint Mag3, Technescan Mag3
- Denmark · Renoscint Mag3, Technescan Mag3
- Spain · Mag3 Radiopharmacy, Mag3 Technescan
- Finland · Technescan Mag3
- France · Technescan Mag 3
- United Kingdom (Northern Ireland) · Renoscan Mag3, Technescan Mag3
- Greece · Technescan Mag3
- Hungary · Renoscint Mag3, Technescan Mag3
- Ireland · Technescan Mag3
- Italy · Medirenoscint, Technescan Mag3
- Malta · Renoscint Mag3
- Netherlands · Technescan Mag3
- Norway · Technescan Mag3
- Poland · Renoscint Mag3
- Portugal · Technescan Mag3
- Sweden · Technescan Mag3
- Slovakia · Technescan Mag3
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cafd6738-0b16-4611-8b75-beb1d1c7f32c GET /v1/drugs/cafd6738-0b16-4611-8b75-beb1d1c7f32c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "1",
"substance": "BETIATIDE",
"productndc": "69945-096",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA019882",
"marketing_category": "NDA"
}See everything about betiatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.